Royal Bank of Canada’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $262M | Buy |
791,515
+200,020
| +34% | +$68.1M | 0.05% | 346 |
|
|
2025
Q4 | $235M | Buy |
591,495
+154,737
| +35% | +$68.5M | 0.04% | 371 |
|
|
2025
Q3 | $199M | Buy |
436,758
+5,923
| +1% | +$2.41M | 0.03% | 428 |
|
|
2025
Q2 | $140M | Buy |
430,835
+93,604
| +28% | +$25.9M | 0.03% | 498 |
|
|
2025
Q1 | $91.1M | Buy |
337,231
+27,044
| +9% | +$6.95M | 0.02% | 577 |
|
|
2024
Q4 | $73M | Sell |
310,187
-100,879
| -25% | -$26.5M | 0.01% | 683 |
|
|
2024
Q3 | $113M | Sell |
411,066
-298
| -0.1% | -$77.6K | 0.02% | 520 |
|
|
2024
Q2 | $100M | Buy |
411,364
+36,940
| +10% | +$5.83M | 0.02% | 518 |
|
|
2024
Q1 | $56M | Buy |
374,424
+116,469
| +45% | +$19.4M | 0.01% | 737 |
|
|
2023
Q4 | $49.4M | Buy |
257,955
+13,849
| +6% | +$2.36M | 0.01% | 791 |
|
|
2023
Q3 | $43.2M | Sell |
244,106
-2,116
| -0.9% | -$404K | 0.01% | 765 |
|
|
2023
Q2 | $46.8M | Buy |
246,222
+30,063
| +14% | +$5.96M | 0.01% | 735 |
|
|
2023
Q1 | $43.3M | Buy |
216,159
+19,579
| +10% | +$4.12M | 0.01% | 740 |
|
|
2022
Q4 | $46.7M | Buy |
196,580
+130,564
| +198% | +$27.8M | 0.01% | 720 |
|
|
2022
Q3 | $13.2M | Sell |
66,016
-15,087
| -19% | -$2.88M | ﹤0.01% | 1348 |
|
|
2022
Q2 | $11.8M | Buy |
81,103
+58,508
| +259% | +$8.3M | ﹤0.01% | 1448 |
|
|
2022
Q1 | $3.69M | Sell |
22,595
-5,606
| -20% | -$854K | ﹤0.01% | 2511 |
|
|
2021
Q4 | $4.78M | Buy |
28,201
+3,609
| +15% | +$671K | ﹤0.01% | 2406 |
|
|
2021
Q3 | $4.64M | Buy |
24,592
+8,464
| +52% | +$1.59M | ﹤0.01% | 2352 |
|
|
2021
Q2 | $2.73M | Sell |
16,128
-71
| -0.4% | -$10.4K | ﹤0.01% | 2790 |
|
|
2021
Q1 | $2.29M | Sell |
16,199
-13,326
| -45% | -$2.01M | ﹤0.01% | 2894 |
|
|
2020
Q4 | $3.84M | Buy |
29,525
+9,962
| +51% | +$1.33M | ﹤0.01% | 2374 |
|
|
2020
Q3 | $2.85M | Sell |
19,563
-4,205
| -18% | -$598K | ﹤0.01% | 2402 |
|
|
2020
Q2 | $3.52M | Buy |
23,768
+857
| +4% | +$116K | ﹤0.01% | 2187 |
|
|
2020
Q1 | $2.49M | Buy |
22,911
+2,579
| +13% | +$298K | ﹤0.01% | 2305 |
|
|
2019
Q4 | $2.34M | Sell |
20,332
-15,782
| -44% | -$1.57M | ﹤0.01% | 2751 |
|
|
2019
Q3 | $2.9M | Sell |
36,114
-4,110
| -10% | -$325K | ﹤0.01% | 2453 |
|
|
2019
Q2 | $2.92M | Buy |
40,224
+26,538
| +194% | +$2.04M | ﹤0.01% | 2473 |
|
|
2019
Q1 | $1.28M | Buy |
13,686
+2,223
| +19% | +$186K | ﹤0.01% | 3012 |
|
|
2018
Q4 | $835K | Buy |
11,463
+1,318
| +13% | +$101K | ﹤0.01% | 3309 |
|
|
2018
Q3 | $888K | Buy |
10,145
+3,014
| +42% | +$303K | ﹤0.01% | 3457 |
|
|
2018
Q2 | $703K | Buy |
7,131
+1,666
| +30% | +$165K | ﹤0.01% | 3512 |
|
|
2018
Q1 | $651K | Buy |
5,465
+2,778
| +103% | +$358K | ﹤0.01% | 3509 |
|
|
2017
Q4 | $341K | Buy |
2,687
+924
| +52% | +$116K | ﹤0.01% | 4066 |
|
|
2017
Q3 | $207K | Buy |
1,763
+280
| +19% | +$23.9K | ﹤0.01% | 4489 |
|
|
2017
Q2 | $118K | Sell |
1,483
-3,877
| -72% | -$248K | ﹤0.01% | 4675 |
|
|
2017
Q1 | $274K | Buy |
5,360
+1,951
| +57% | +$90.2K | ﹤0.01% | 4131 |
|
|
2016
Q4 | $128K | Sell |
3,409
-54,271
| -94% | -$2.27M | ﹤0.01% | 4746 |
|
|
2016
Q3 | $3.91M | Buy |
57,680
+6,366
| +12% | +$449K | ﹤0.01% | 2075 |
|
|
2016
Q2 | $2.85M | Buy |
51,314
+19,827
| +63% | +$1.25M | ﹤0.01% | 2253 |
|
|
2016
Q1 | $1.98M | Buy |
31,487
+5,382
| +21% | +$358K | ﹤0.01% | 2466 |
|
|
2015
Q4 | $2.46M | Buy |
26,105
+13,884
| +114% | +$1.29M | ﹤0.01% | 2369 |
|
|
2015
Q3 | $982K | Sell |
12,221
-455
| -4% | -$50.6K | ﹤0.01% | 2873 |
|
|
2015
Q2 | $1.52M | Sell |
12,676
-4,777
| -27% | -$571K | ﹤0.01% | 2547 |
|
|
2015
Q1 | $1.82M | Buy |
17,453
+9,619
| +123% | +$975K | ﹤0.01% | 2354 |
|
|
2014
Q4 | $759K | Sell |
7,834
-16,330
| -68% | -$1.51M | ﹤0.01% | 3165 |
|
|
2014
Q3 | $1.89M | Buy |
24,164
+16,401
| +211% | +$1.06M | ﹤0.01% | 2358 |
|
|
2014
Q2 | $490K | Buy |
7,763
+6,507
| +518% | +$387K | ﹤0.01% | 3418 |
|
|
2014
Q1 | $84K | Sell |
1,256
-2,053
| -62% | -$159K | ﹤0.01% | 4632 |
|
|
2013
Q4 | $214K | Sell |
3,309
-1,910
| -37% | -$114K | ﹤0.01% | 4104 |
|
|
2013
Q3 | $334K | Buy |
5,219
+1,694
| +48% | +$84.4K | ﹤0.01% | 3705 |
|
|
2013
Q2 | $109K | Buy |
+3,525
| New | +$93.8K | ﹤0.01% | 4255 |
|
Other funds holding ALNY
VPM
VCM
Royal Bank of Canada's ALNY Position: Q1 2026 in Review
Royal Bank of Canada increased its Alnylam Pharmaceuticals (ALNY) stake by 34% in Q1 2026, buying an estimated $68.1M and bringing the position to 791,515 shares worth $262M. The position accounts for 0.05% of the portfolio, ranked #346.
Royal Bank of Canada first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Royal Bank of Canada held 791,515 shares of Alnylam Pharmaceuticals worth $262M as of Q1 2026.
- Royal Bank of Canada bought 200,020 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $68.1M.
- Alnylam Pharmaceuticals made up 0.05% of Royal Bank of Canada's portfolio in Q1 2026, its #346 holding.
- Royal Bank of Canada first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.